The GLP-1 landscape in India is moving fast. We track what's actually changed — new launches, pricing, regulation, and the science on the horizon — so you don't have to sort fact from hype yourself.
Monthly GLP-1 drug sales in India grew just 2.3% in June 2026, down sharply from 58.4% growth in April, according to market research firm Pharmarack. The rush that followed March's patent expiry appears to be settling into a steadier, more considered adoption curve rather than continuing to accelerate.
Source: BloombergDr Reddy's Laboratories became the first company to offer an oral semaglutide tablet in India, branded Obeda, priced at ₹99, ₹135 and ₹225 for the 3mg, 7mg and 14mg doses respectively. The company also sells an injectable version of Obeda in a pre-filled pen at roughly ₹4,200 a month.
Source: Business TodayThe Indian government issued national guidelines restricting GLP-1 prescriptions to endocrinologists, internal medicine specialists and cardiologists — these medicines cannot be bought over the counter. A related advisory cracked down on misleading advertising, and dozens of pharmacies, wholesalers and weight-loss clinics were inspected for unauthorised sales.
Source: Press Information Bureau (PIB), Government of IndiaNovo Nordisk's core semaglutide patent expired in India on March 20, 2026, and generic versions launched within hours. Zydus Lifesciences brought out Semaglyn, Mashema and Alterme in a reusable multi-dose pen (roughly ₹2,200/month); Dr Reddy's launched Obeda; Glenmark's GLIPIQ undercut everyone at ₹325–440 a week. Branded Ozempic at the same dose had cost roughly ₹8,100/month — the new generics run from about ₹1,290 to ₹4,200.
Source: Business Standard, Pearce IPCipla launched Yurpeak, its branded version of Eli Lilly's tirzepatide, as a once-weekly KwikPen injection in six strengths (2.5mg–15mg) for obesity and type 2 diabetes. It's priced the same as Mounjaro, and Cipla says it's prioritising distribution beyond India's metro cities.
Source: Cipla press releaseEli Lilly's orforglipron — an oral, small-molecule GLP-1 with no food or water restrictions — beat oral semaglutide head-to-head in its ACHIEVE-3 Phase 3 trial on both blood sugar control and weight loss, and global regulatory filings began in 2026. Separately, retatrutide, a 'triple agonist' that acts on three gut-hormone receptors at once, produced an average 28.3% weight loss over 80 weeks in its pivotal Phase 3 trial — the largest reduction reported yet for an obesity drug. Neither medicine is approved or available in India yet.
Source: Eli Lilly, New England Journal of MedicineFrom social media reels to family WhatsApp groups, GLP-1 medicines became a fixture of Indian pop-culture conversation in 2026, with visible transformations among public figures fuelling speculation and FOMO. It's worth being careful here: most individuals named in that speculation have not confirmed using these medicines, and several have explicitly denied it. The bigger, verifiable story is structural — patent expiry, a 40+ brand generic market, and new government guardrails — not any single celebrity's routine.
Source: Forbes IndiaThis page is updated periodically as new India-specific developments and research emerge. Last reviewed: July 2026.